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Abstract
Background—The aim of the study was to examine the efficacy of a collaborative care 
intervention to reduce depression, pain and fatigue and improve quality of life.
Participants—A total of 261 patients with advanced cancer and 179 family caregivers were 
randomized to a web-based collaborative care intervention or enhanced usual care. The 
intervention included (1) a website with written and audiovisual self-management strategies, 
bulletin board, and other resources; (2) visits with a care coordinator during physician appointment 
every two months; and (3) telephone follow up every two weeks. Primary patient outcomes 
included measures of depression, pain, fatigue, and health related quality of life. Secondary 
outcomes included Interleukin (IL)-1α, IL-1β, IL-6, IL-8, Natural Killer (NK) cell numbers, and 
caregiver stress and depression.
Results—At baseline, 51% of patients reported one or more symptoms in the clinical range. For 
patients who presented with clinical levels of symptoms, and were randomized to the intervention, 
reductions in depression (Cohen’s d=0.71), pain (Cohen’s d=0.62), and fatigue (Cohen’s d=0.26) 
and improvements in quality of life (Cohen’s d =0.99) were observed when compared to the 
enhanced usual care arm at 6-months. Reductions in IL-6 (phi=0.18), IL-1β (phi=0.35); IL-1α 
(phi=0.19); IL-8 (phi=15) and increases in NK cell numbers (phi=0.23) were observed when 
compared to enhanced usual care arm at 6-months. Reductions in caregiver stress (Cohen’s 
d=0.75) and depression (Cohen’s d=0.37) were observed at 6-months for caregivers whose loved 
one was randomized to the intervention arm.
Conclusions—Integration of screening and symptom management into cancer care is 
recommended.
Introduction
Symptom management is critical to maintain quality of life in patients with life limiting 
conditions. In 2002, the National Institute of Health State of the Science Consensus 
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conference concluded that the three most common and debilitating symptoms associated 
with cancer were depression, pain and fatigue and this remains true today despite the 
advances that have been made in symptom management.1–9 To date, several interventions 
have been tested to reduce individual symptoms with success.10–20 However, because these 
symptoms are often comorbid and can exacerbate one another, interventions that target 
multiple symptoms are warranted. An intervention designed to treat these symptoms 
simultaneously is warranted to improve quality of life of patients with advanced cancer.
Stepped collaborative care interventions have been widely employed in the primary care 
setting for the treatment of depression and more recently have been utilized to treat other 
symptoms (e.g., pain) in a variety of settings.21,22,23 A recent meta-analyses concluded that 
collaborative care interventions were superior to usual care and are more cost-effective than 
face to face and pharmacological treatment for depression.24
Collaborative care interventions have begun to be extended to oncology settings. Dwight-
Johnson and colleagues (2005) tested a collaborative care intervention in patients with 
cancer and comorbid depression.25 Compared to usual care, the patients randomized to the 
intervention arm experienced reductions in depression and pain.25,14,26 deRaaf and 
colleagues also tested non-pharmacological strategies administered by a nurse, in 
collaboration with the oncologist, to reduce fatigue.27 These investigators demonstrated that 
the intervention was effective in reducing fatigue in patients with cancer.27
Recent advances in technology have made the scalability and cost-effectiveness of 
collaborative care interventions even greater. Collaborative care interventions reduce barriers 
associated with face to face treatment including the need for additional appointments while 
undergoing treatment for cancer; the stigma associated with seeking mental health or 
services from a pain center; and the costs associated with treatment, transportation, and 
absenteeism for the patient and/or caregiver. Furthermore, the web-based collaborative care 
interventions permits the dissemination of a standardized empirically based treatments that 
are individually tailored and are available to patients who may not have otherwise had access 
to treatment for their cancer-related symptoms. The use of a “stepped” care approach 
permits the individualization of treatment based on the patients’ needs and provide care for 
patients who require varying levels of care in a cost-effective manner.28,29
Advanced cancer patients in the palliative care setting and those in underserved areas report 
the most severe symptoms due to the tumor burden, limited access to treatment due to the 
advanced stage of disease, and the least frequent contact with health care professionals, 
particularly once treatment has ended. It has also been demonstrated that those from 
socioeconomically disadvantaged background have higher symptom burden and less access 
to palliative care services.30
The aims of the present study were to: (1) understand the prevalence of patient report of 
individual and multiple symptoms (e.g., pain, fatigue, and depression) in the context of 
advanced cancer; (2) test the efficacy of a web-based stepped collaborative care intervention 
in a predominantly underserved advanced cancer patient population; and (3) test the efficacy 
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of the web-based stepped collaborative care intervention on biomarkers of inflammation and 
caregiver stress and depression.
Methods
Design
The study was a randomized controlled trial of a web-based collaborative care intervention 
for patients diagnosed with cancer. The study consisted of two arms (1) web-based stepped 
collaborative care intervention, and (2) enhanced usual care. Patients and family caregivers 
were enrolled in the study and they were assessed at the time of randomization and then at 6-
months. Please see Figure 1 for the CONSORT flow diagram with regard to enrollment and 
follow-up.
Sample
Patients diagnosed with hepatocellular, cholangiocarcinoma, gallbladder, neuroendocrine, 
and pancreatic carcinoma or other primary cancers that have metastasized to the liver (e.g., 
ovarian, breast, colorectal) were enrolled in the study. The majority of patients received 
regional chemotherapy (transarterial chemoembolization) or radiation (90 yttrium) or 
surgery. The primary side effect of these treatments is fatigue. A minority of patients 
develop nausea and vomiting or other symptoms. Chronic pain is also not common as a 
result of the treatment. For those who underwent surgery, the side effects were pain and 
fatigue after surgery but last approximately 2 weeks. The interviews and blood draws to 
evaluate the efficacy of this intervention were performed 7 weeks after the cancer-related 
treatment to avoid capturing treatment-related side effects. The inclusion criteria were: (1) 
biopsy and/or radiograph proven diagnosis of cancer; and (2) age greater than or equal to 21 
years. The exclusion criteria included: (1) less than 21 years of age, (2) lack of fluency in 
English, (3) evidence of thought disorder, delusions, hallucinations, or suicidal ideation 
(these patients were referred for immediate face to face and/or psychotropic medication). 
The inclusion criteria did not include a specific level for any of the three target symptoms as 
we expected that patients would experience one or more of these symptoms over the course 
of the intervention.
Data Collection
We used baseline and 6-month data for the purposes of this study. All data was collected by 
trained interviewers using a structured computerized interview. The interviewers were 
blinded to the study arm assignment. The primary outcomes to assess the efficacy of the 
intervention included the Center for Epidemiological Studies-Depression31, the Brief Pain 
Inventory (BPI)32, the Functional Assessment of Cancer Therapy – Anemia (FACT-AN)33, 
and the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep).24 Secondary 
outcomes included serum cytokines levels and Natural Killer Cell (NK) cell numbers. 
Although the caregivers were not the target of the intervention; caregiver stress and 
depression were also assessed using the Caregiver Quality of Life Index-Cancer Scale 
(CQOLC)34 and the Center for Epidemiological Studies-Depression scale.31
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Randomization to Study Arms
The patients were randomly assigned to one of two arms of the study (web-based stepped 
collaborative care intervention versus enhanced usual care) based on a block randomization 
design according to gender and vascular invasion (gender: male/female; macroscopic 
vascular invasion of the portal or hepatic veins as determined by imaging and/or histology: 
yes/no).
Allocation Concealment
Allocation concealment was achieved through the use of a random number table that 
assigned consecutive patients across group. A research assistant who was not part of the 
study placed the trial assignments in opaque envelopes consecutively by group. These 
opaque envelopes were sealed, numbered serially, and placed into four numbered containers, 
one for each stratification subgroup (male and vascular invasion; male and no vascular 
invasion; female and vascular invasion; female and no vascular invasion). The statistician put 
the randomization table in a sealed envelope to be opened only at the end of the trial.
Web-based Collaborative Care Intervention
The web-based collaborative care intervention included access to a psycho-educational 
website (see Figure 2) and to a collaborative care coordinator with training and experience 
with cognitive-behavioral therapy (CBT) and psycho-oncology. The patient had telephone 
contact with the care coordinators approximately every 2 weeks and face to face contact 
with the care coordinator in the oncology outpatient clinic and/or hospital approximately 
every 2 months. The care coordinator would provide CBT and/or recommendations for 
pharmacological management of symptoms if the patient preferred medication to CBT or in 
addition to CBT. For example, the care coordinator would recommend to the medical team 
or the patients’ primary care physician (PCP) if an antidepressant was indicated or if the 
patients’ pain was not well managed (e.g., addition of a long acting pain medication, referral 
to pain center).
More frequent contact occurred when a symptom was more severe and/or needed multiple 
contacts to manage. The dose and active ingredients of the intervention was recorded using 
an ACCESS database. The objective of the intervention was to treat cancer-related 
symptoms including depression, pain, and fatigue. The presence and severity of these 
symptoms varied over the course of treatment and patients were treated as symptoms were 
reported to the clinician. A stepped approach was used so if the patient’s symptoms did not 
improve increasingly intensive strategies were used to decrease symptom burden.
The website included (1) psycho-educational information with regard to depression, pain, 
fatigue, nausea and vomiting and sleep; (2) a self-management area where the patient could 
record their symptoms and monitor changes through graphical depictions; (3) an area for 
journaling; (4) a chat room that connected the patient to other patients enrolled in the study, 
(5) an audiovisual library that included relaxation techniques and educational videos by the 
patient’s nurse coordinators; and (6) resource library. The website also includes a text to 
voice option to address issues of literacy and larger font for older adults.
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The care coordinators were Master’s level or Ph.D. therapists trained in cognitive-behavioral 
therapy and experienced in evaluating and treating patients diagnosed with cancer. The care 
coordinators would have face to face contact with the patient in the outpatient cancer clinic 
or in the hospital when the patient visited the hospital for follow up or treatment. The care 
coordinators contacted the patients by phone but were also available as needed to the patient 
for questions and concerns. The care coordinator provided information to the medical team 
about any changes in the patient’s symptoms that may warrant changes in treatment (e.g., 
increasing the current dose of SSRI, change medication, add psychotherapy). However the 
medical team may or may not accept the care coordinators recommendations. For example, 
if a patient is being treated with an selective serotonin reuptake inhibitor (SSRI) and the care 
coordinated confirmed with the patient s/he had been adherent to the medication regimen, 
treated for the appropriate duration (e.g., at least 6–8 weeks), and the patient continued to 
meet the DSM 5 diagnostic criteria for depression; the care coordinator would discuss with 
the patient if s/he was interested also in changing their treatment. If so, the care coordinator 
would then relay the patient’s desires to the medical team.
Fidelity of the Intervention
The therapists were trained using a 300 page intervention manual which included the 
evaluation of depression, pain, and fatigue and cognitive-behavioral treatment of these 
symptoms. The care coordinators were supervised by a clinical health psychologist who has 
received additional training and certification by the American Psycho-Oncology Society for 
maintaining the fidelity of psychosocial interventions. The clinical psychologist provided 
training and weekly supervision of the care coordinators and to assess and maintain 
adherence to the intervention protocol. If the care coordinator was not adhering to the study 
protocol, s/he would receive additional training and supervision.
Enhanced Usual Care
The enhanced usual care arm of the study was “usual care” provided by the medical team in 
addition to the assessment of symptoms and blood draws at the same time as the patients 
randomized to the intervention arm to assess the efficacy of the intervention. For ethical 
reasons, if a patient or caregiver scored high on the CES-D (≥16) or the BPI average pain 
score (>5) the patient was contacted by a care coordinator and provided education about 
their symptoms and referrals to a mental health professional in their community or to their 
Primary Care Physician (PCP) for pharmacological treatment for depression. If the patient 
scored high on the BPI average pain item (≥5), s/he was referred to a pain center or an expert 
in symptom management if it was cancer related. Of the patients who were referred for 
treatment, <1% pursued any type of psychotherapy and/or treatment with medication. 
Despite the lack of patients following through with treatment for their symptoms, we 
provided patients with elevated scores in the usual care arm “attention” and it is plausible 
that providing such contact may have sensitized these participants to pursue additional 
clinical care at a later point in time.”
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The study did not commence until the University of Pittsburgh’s Institutional Review Board 
approved the study. The medical team referred the patient and family member and if the 
patient agreed, the study team member would explain the risks and benefits of the study. If 
the patient provided written informed consent, s/he was then randomly assigned to the 
intervention or enhanced usual care arm. A psychiatric intake was then conducted by the 
care coordinator either the day of consent or by phone to determine the patient needs. If the 
patient was randomly assigned to the intervention arm, the intervention commenced after the 
baseline telephone interview was completed.
Data Analysis
The data was entered and verified in SPSS version 21. Descriptive statistics were performed 
to characterize the sample and examine the distribution of data. The number of visits to each 
page of the website and duration was recorded in real time. A 2×4 mixed analysis of 
variance (ANOVA) was performed on CESD, FACT-Fatigue, BPI average pain score, and 
FACT-Hepatobiliary as a function of treatment group and time using General Linear Mixed 
Models (GLMM) approach. The within-subjects IV is time (Baseline and 6 months). The 
between-subjects IV is treatment group (usual, intervention). Evidence became available 
over the course of the trial by Hart and colleagues (2012) that suggested that two separate 
GLMM analyses be performed, first with all participants and then with patients with 
clinically significant symptoms. Clinically levels of symptoms a CES-D score ≥16, average 
pain ≥3 or a FACT-Fatigue score ≥26. Prior research has also shown that a 5–6 point 
difference in the overall FACT-G is clinically meaningful.35 The effect size measures the 
magnitude of the relationship and was defined using a Cohen’s d for the psychological and 
physical outcomes (small effect <0.20; medium effect size=0.30–0.70; and a large effect size 
>0.80) and a phi was used for the biological outcomes (small effect<0.10; medium 
effect<0.30; large effect<0.50).
Results
A total of 340 participants were approached for enrollment in the study. Of the 340 
participants, 261 (77%) agreed to participate. A CONSORT flow diagram (Figure 1) depicts 
the number of patients approached for enrollment, randomization, attrition due to death and 
follow up of patients from baseline to 6-months.
Sociodemographic, disease, and treatment related characteristics can be found in Table 1. Of 
the 261 participants enrolled in the study, the majority of patients were male (73%). The 
mean age was 61 years (SD=11). No significant difference between the two arms of the 
study were observed on age, gender, ethnicity, diagnosis, treatment, or baseline scores on the 
CES-D, FACT-Fatigue, BPI average pain score (0–10), or overall quality of life (FACT-G).
Website Usage
Figure 2 depicts a screen shot of the home page of the website. The website contained over 
500 pages of content.
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Ninety-two percent of the participants who participated reported that they had access to a 
computer at home or work. Of the 8% who did not have access to a computer, 6% borrowed 
a laptop computer from the study team and 2% preferred printed information from the 
website as needed. The patients were provided the website username and password if they 
were randomized to the intervention arm of the study. The patients were not directed to use 
the website over the course of the intervention. Table 2 depicts the number of visits and 
duration on each of the major sections of the website.
Prevalence of cancer-related symptoms
At the time of randomization, a total of 132 patients (51%) reported one or more symptoms 
in the clinical range. Eighty-two of the 261 patients (31%) reported depressive symptoms in 
the clinical range of the CES-D (>16); 71 (27%) patients reported an average level of pain in 
the last week to be greater than or equal to 3; and 90 patients (35%) reported moderate to 
severe fatigue. Of these patients who reported any of the three symptoms, 6.5% of patient 
reported only depression, 6.1% only having pain, 8.8% of patient reported fatigue only, 
8.0% of patient reported depression and fatigue, and 3.4% reported depression and pain, 
4.2% reported pain and fatigue, and 13.4% reported all three symptoms at baseline. See 
Table 3.
The website was developed for patients who may have low literacy or sensory deficits. 
Patients who were from a socioeconomically disadvantaged background had higher levels of 
depression, pain, and fatigue. Patients from socioeconomically disadvantaged backgrounds 
reported significantly higher levels of depression [F(2,211)=8.3, p<0.001]; pain [F(2, 
136)=6.9, p<0.001]; fatigue [F(2,209)=5.3, p=0.006]; and poorer quality of life 
[F(2,170)=7.3, p<0.001].
Intervention versus enhanced Usual Care
For the patients who had clinical levels of depressive symptoms measured by the CES-
D≥16; a medium effect size (Cohen’s d= 0.71) was observed at 6-months follow up [t (14) 
=1.41, p=0.182]. The second symptom that was targeted as part of the collaborative care 
intervention was pain. At 6 months, a reduction of pain, with a medium effect size of 
(Cohen’s d=0.62) was observed between the intervention and enhanced usual care arm [t (9) 
=1.76, p=0.112]. We observed the intervention group was superior to the enhanced usual 
care arm in that reductions of fatigue were observed at 6 months with an effect size of 0.26 
[t(15)=1.80, p=0.09]. Statistically and clinically significant changes in overall quality of life 
were observed with an effect size of 0.99 from baseline to 6-months follow-up [t (16) =
−2.19, p=0.05]. No significant difference was observed by treatment type for patients in the 
intervention versus the usual care arm of the study (Chi-square=0.792, p=0.851; intervention 
arm = 62.5% underwent regional chemotherapy or radiation and the remaining 37.5% 
surgery and usual care arms= 71.4% underwent regional chemotherapy or radiation and the 
remaining 28.6% surgery).
Using an intent-to-treat analyses the effect size (phi) was small to medium effect size was 
observed at 6-months for IL-6 (Phi=0.337; Chi-square=1.59, p=0.207); IL-1β (Phi=0.378; 
Chi-square=2.0, p=0.149); and IL-8 (Phi=0.304; Chi-square=1.30, p=0.304). A medium 
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effect size was observed for NK cell number (Phi=0.491) at 6-months [Chi-square=3.62, 
p=0.057]. See Table 5.
Post-hoc analyses using Mann Whitney U demonstrated that clinical levels of fatigue were 
associated with Natural Killer cells [Mann Whitney U=10, p=0.066] with patients reporting 
greater levels of fatigue having lower Natural Killer cell numbers (Mean rank=5.33) when 
compared to those with reported lower levels of fatigue (Mean rank=13.52). Clinical levels 
of pain were not found to be significantly associated with any of the biomarkers measured. 
A trend toward significance was observed for depression and IL-8 [Mann Whitney U=3.385, 
p=0.184] with clinical levels of depression being associated with a higher levels of IL-8 
(Mean rank=12.92) when compared to patients without clinical levels of depression (Mean 
rank=8.14). A trend toward significance was observed with regard to the association 
between overall quality of life, which may reflect improvement in all symptoms, and IL-1β 
[Spearman rho=0.357, p=0.103] and IL-1α [Spearman rho=0.339, p=0.168].
Although not a target of the intervention, caregivers with patients randomized to the 
intervention arm had reductions in stress and depression. When only caregiver with patients 
who had clinically significant symptoms were included in the analyses, an effect size of 
0.748, was observed for caregiver stress at 6-months follow up and 0.372 for depression. See 
Table 6 for means and standard deviations.
Demographic characteristics such as age, gender, and educational level as well as disease 
specific variables of the patient (e.g., tumor size, lesion number) were not found to be 
significant predictors of the patients’ reported depressive symptoms. Cross-lagged panel 
analyses, while adjusting for gender, yielded the findings that patients’ baseline depressive 
symptoms significantly predicted the caregivers’ reported stress at baseline and 4 months 
follow up. The caregivers’ reported stress level at 2-months was also predicted by the 
patients’ level of depressive symptoms. [Chi-square (9, N = 119) = 5.561, p = .783; RMSEA 
= .000, CFI = 1.000, SRMR = .031]. See Figure 4.
At baseline, the patients’ quality of life also significantly predicted the caregivers’ 
depressive symptoms and a trend was observed between patient quality of life and the 
caregivers’ level of depressive symptoms at 2-months follow-up. [Chi-square (10, N = 120) 
= 7.986, p = .630; RMSEA = .000, CFI = 1.000, SRMR = .037]. See Figure 5.
Discussion
Once used only in primary care settings, collaborative care interventions are becoming 
increasingly utilized in other medical settings, including oncology, to treat depression and 
other symptoms. The findings of this study demonstrate that a web-based stepped 
collaborative care intervention is feasible, acceptable, and efficacious in the reduction of 
depressive symptoms, pain and improving quality of life in advanced cancer patients. Based 
on a recent meta-analysis, this is the first web-based collaborative care intervention to target 
and reduce three of the most distressing symptoms to cancer patients.36 Furthermore, in 
addition to reducing symptoms, the intervention reduced inflammation, improved caregiver 
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outcomes such as stress and depression, and demonstrated clinically meaningful changes in 
patients’ quality of life.36
The access to computers and the internet was relatively high despite the age and 
socioeconomic status of the patients. Nearly half of the patients enrolled reported a family 
income of $30,000 or less yet the majority had access to a computer at home or work. 
Patients primarily used the website at the time of diagnosis and then when they were 
confronted with a recurrence and/or new treatment. Post-hoc analysis of the timing of 
website usage showed that patients tended to use the website after office hours (between 5–
9pm after access to care coordinators and nurses was less available).
The findings of this study also suggest that more than one symptom can be targeted and 
treated at the same time and that the reduction of depression and pain also improved overall 
quality of life. Our findings were consistent with a systematic review by Uitterhoeve and 
colleagues (2004) which found that psychosocial interventions were effective in improving 
quality of life in patients with advanced cancer.37 Nonetheless, these interventions have not 
become standard of care in the oncology setting despite the call for screening and treatment 
of distress (IOM, American College of Surgeons, ASCO).
A survey in 2005 found that only 53% of NCCN centers who responded to the survey (83% 
response rate) performed screenings for distress and/or depression and only three performed 
routine screenings.38,39 Recently, the Institute of Medicine (IOM) and the NCCN published 
guidelines for the screening and treatment of distress40 and in the last two years the 
American College of Surgeons (ACoS) and the American Society for Clinical Oncology 
(ASCO) have included screening for distress/depression as a quality indicator.41 The quality 
indicators stipulate that the oncologist provide: (1) evidence in the medical record that the 
patient’s emotional well-being was assessed within 1 month of their first visit, and (2) if an 
emotional problem exists that there was action taken to address the problem or there was an 
explanation provided for why no action was taken. Despite these guidelines, and 
introduction of these quality indicators; routine screening and treatment for distress in the 
context of oncology settings still remains rare.42 Jacobsen has suggested, that in part, this is 
the result of inconsistent findings that have been reported with regard to the efficacy of 
psychosocial interventions in the treatment of depression.43 Jacobsen recently concluded 
that the adoption of routine screening may be greater if there was stronger evidence that 
screening and treatment of patients predicted better clinical outcomes and that randomized 
controlled trials were needed.42
The inconsistencies in the efficacy of psychosocial interventions have been in part due to the 
inclusion of patients in interventions studies with and without clinical levels of depression or 
other symptoms. A recent meta-analysis reviewed more than 7700 studies and found that 
only 10 randomized controlled trials have been performed testing the efficacy of depression 
treatment for cancer patients with clinical levels of depression.44 Of the 1362 participants 
included in the meta-analyses, the random effects model showed interventions using CBT 
and/or SSRIs to be superior to control conditions in reducing depressive symptoms in people 
diagnosed with cancer.44 Although the interventions were found to be effective (e.g., 
statistically significant differences between the intervention and control arms, the effect sizes 
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for the majority of the interventions remain modest. Although the sample size was small, we 
observed small to medium effect sizes for primary and secondary outcomes.
The web-based collaborative care intervention was not shown to be particularly effective in 
reducing fatigue. However, the effect sizes for our study were similar to other interventions 
targeting fatigue alone. However, Kangas and colleagues (2008) concluded from their meta-
analytic review, that patients randomized to a psychosocial or physical activity interventions 
when compared to patients randomized to the standard of care arms was effective at 
reducing fatigue.45 Multimodal exercise and walking programs, restorative approaches, 
supportive-expressive, and cognitive-behavioral psychosocial interventions showed the most 
potential for ameliorating cancer-related fatigue.45 Although cognitive behavioral strategies 
and restorative approaches were employed in the present study, the advancing disease in this 
sample may have impacted the lack of improvement in this symptom.
Not only were psychological and physical symptoms reduced but we observed reductions in 
pro-inflammatory cytokines as well as increases in the number of NK cells in those who 
were randomized to the intervention arm of the study. These changes in biomarkers were 
also compared to that of normal controls and found to be clinically meaningful as a greater 
number of patients in the intervention arm achieved “normal” levels (when compared to 
healthy controls) of these cytokines and NK cell numbers. Further research is warranted to 
determine if these changes in inflammation and tumor surveillance translate into slowed 
tumor growth or development of metastases.
In a recent meta analyses, a positive association between depression and pro-inflammatory 
cytokines including IL-6, TNFα, and IL-1β, in the serum and cerebrospinal fluid, and NK 
cell numbers was observed.46,47,48,49 Similar associations between depression and 
biomarkers of inflammation and NK cells have also been reported in those diagnosed with 
cancer.50,51 We included six cytokines and NK cell numbers secondary to their link with the 
targeted symptoms and with survival across cancer types.52–56
In the present study we observed a link between fatigue and lower Natural Killer cell 
numbers. Natural Killer cells have been extensively studied in chronic fatigue and low 
numbers associated with higher levels of fatigue.57 Depression has been linked to higher 
levels of IL-6 and lower NK cell numbers in prior studies; however in the present study 
higher levels of depression were associated with higher serum levels of IL-8. Interleukin-8 is 
important in the context of cancer as it induces phagocytosis, promotes angiogenesis, 
increases the proliferation and survival of tumor cells, and potentiates the migration of tumor 
cells.58 Intereukin-8 also is considered a pro-inflammatory mediator and secretion of this 
protein is associated with increased oxidant stress and recruitment of inflammatory cells 
resulting in localized inflammation.58 Finally, improvements in overall quality of life were 
associated with decreased serum levels of IL-1α and IL-1β. Interleukin-1 is important in the 
regulation of immune and inflammatory responses and these cytokines are associated with 
tumorigenesis, tumor invasion, metastases across cancer types.59,60
Although less studied, evidence is mounting with regard to the effectiveness of psychosocial 
or pharmacological interventions in the modulation of ANS and HPA hormonal activity.61 A 
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meta-analysis concluded that pharmacological treatments for depression reduced depressive 
symptoms when compared to controls but were not found to reduce TNFα in a sample from 
the general population. Treatment did reduce IL-1β and in most studies IL-6 but SSRIs 
appeared to have the greatest effects on changes of IL-6.62 Only a few studies have 
examined the reduction of biomarkers after behavioral or pharmacological treatments in 
cancer patients despite the plethora of evidence that depression increases the risk of 
mortality in the context of cancer.63,64
The reduction of patients’ symptoms also effectively reduced the caregivers’ stress and 
depression. Although prior research has demonstrated the effect of patient functioning on the 
caregiver, this is the first study to observe that with improved patients’ symptoms, the family 
caregivers’ quality of life was improved.65–68 The reduction of stress and depression may 
also have effects on the caregivers’ health by reducing the risk of cardiovascular disease 
which has been shown to be associated with caregiving.69–77
One of the major challenges with psychosocial intervention trials in general is the low 
enrollment rates and high attrition. While we observed adequate enrollment rates, 
particularly considering the advanced stage of cancer in which patients presented and the 
inclusion of family caregivers, attrition particularly due to death was high in this trial. 
However, we found that most patients remained active in the intervention but may have not 
completed outcomes measures. Only 8% withdrawal from the intervention was observed 
over the course of 6 months. The high rate of attrition in the trial was secondary to death, 
which is reflective of the palliative care setting. Attrition was also affected by the length of 
the battery of questionnaires used to measure the efficacy of the interventions as well as the 
frequency of the questionnaires. It would be recommended in future studies to reduce the 
number of questionnaires as well as the frequency of administration to decrease attrition in 
the assessment of outcomes.
Screening for distress has now been recommended by several organizations (e.g., National 
Comprehensive Cancer Network, Institute of Medicine, College of Surgeons, American 
Society for Clinical Oncology) yet screening for distress and treatment remains rare in the 
oncology setting. Several barriers exist with regard at the patient and provider level as well 
as at the macrolevel (e.g., institutions, insurers). Until these barriers can be overcome, it is 
likely that despite the recommendations that screening of symptoms and treatment will 
remain rare in the context of cancer.
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CONSORT diagram of enrollment and 6-months follow up
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Socioeconomic disadvantage and symptom burden
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Patients’ depressive symptoms and caregiver stress from baseline and 2- and 4-months 
follow-Up
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Patient health-related quality of life and the caregiver depressive symptoms from baseline 
and 2- and 4-months follow-Up
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Table 1
Sociodemographic and disease specific characteristics (exact p-values are reported for two-way chi-square 





Variable n (%) Intervention vs Usual Care
p-value
n (%) Intervention vs Usual Care
p-value
Gender (n, % male) 190 (73) 0.577 94 (71) 0.128
Age (Mean, SD) 61 (11) 0.751 60 (11) 0.707
Race (n, %) 0.779 0.188
 Caucasian 224 (86) 111 (84)
 African American 24 (9) 16 (12)
 Asian-American 3 (1) 1 (1)
 Hispanic 1 (0)
 Other 1 (0)
Diagnosis 0.897 0.211
 HCC and CCC 167 (64) 80 (61)
 Other Primary Cancers with Liver Metastases 94 (36) 52 (39)
Treatment (n, %) 0.145 0.505
 Regional Therapy 133 (51) 68 (52)
 Surgery 54 (21) 29 (22)
HCC=Hepatocellular carcinoma; CCC=Cholangiocarcinoma
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Table 2
Presentation of symptoms at diagnosis
Symptom(s) Prevalence at Diagnosis
Depression only (≥16) 6.5%
Pain only (≥3) 6.1%
Fatigue only (≥26) 8.8%
Depression (≥16) + Fatigue (≥26) 8.0%
Depression (≥16) + Pain (≥3) 3.4%
Pain (≥3) + Fatigue (≥26) 4.2%
Pain (≥3), Fatigue (≥26), + Depression (≥16) 13.4%
Total Cancer-Related Symptoms 50.4%
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